Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211676 | 0.81 | — | — | |
| SCHEMBL14107874 | 0.79 | CRBN (0.40) | CRBNLMNAPKMOR51E2LTA4H | |
| SCHEMBL4498693 | 0.78 | OR51E2 (0.43) | CRBNLMNAPKMOR51E2LTA4H | |
| SCHEMBL15333289 | 0.76 | LMNA (0.38) | CRBNLMNAPKMOR51E2LTA4H | |
| SCHEMBL14941658 | 0.76 | LMNA (0.38) | CRBNLMNAPKMOR51E2LTA4H | |
| SCHEMBL15330711 | 0.73 | LMNA (0.36) | CRBNLMNAPKMOR51E2LTA4H | |
| SCHEMBL11389517 | 0.73 | MEN1 (0.43) | LMNAPKMALDH1A1 | |
| SCHEMBL3430001 | 0.72 | — | — | |
| SCHEMBL2904306 | 0.72 | SIGMAR1 (0.62) | CRBNLMNAPKMLTA4HPOLB | |
| SCHEMBL4511967 | 0.72 | TP53 (0.42) | CRBNLMNAPKMOR51E2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-09-14 | — | — | US | disclosed |
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-13 | — | — | US | disclosed |
| US-10556905-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-11 | — | — | US | disclosed |
| EP-2857401-B1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | MEIJI SEIKA PHARMA CO LTD (JP) | 2019-09-18 | — | — | EP | disclosed |
| US-20180258089-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-09-13 | — | — | US | disclosed |
| US-10023573-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-07-17 | — | — | US | disclosed |
| US-20170233393-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2017-08-17 | — | — | US | disclosed |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-9181250-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857401-A1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | Meiji Seika Pharma Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | CRBN 82/4885LMNA 647/4885PKM 4573/4885 |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | CRBN 3232/4885LMNA 4323/4885PKM 4270/4885 |
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | CRBN 82/4885LMNA 647/4885PKM 4573/4885 |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, MRPL21, FNTB | CRBN 459/4885LMNA 1109/4885PKM 3470/4885 |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, FN1, FNTB | CRBN 539/4885LMNA 1112/4885PKM 3432/4885 |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | CRBN 82/4885LMNA 647/4885PKM 4573/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | CRBN 3232/4885LMNA 4323/4885PKM 4270/4885 |
| US-20180258089-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | CRBN 82/4885LMNA 647/4885PKM 4573/4885 |
| US-10023573-B2 | Beta-lactamase inhibitor and process for preparing the same | FN1, FNTB, CPN1 | CRBN 100/4885LMNA 324/4885PKM 4251/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | CRBN 82/4885LMNA 647/4885PKM 4573/4885 |
| US-10556905-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | CRBN 82/4885LMNA 647/4885PKM 4573/4885 |
| US-20170233393-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | FN1, FNTB, CPN1 | CRBN 100/4885LMNA 324/4885PKM 4251/4885 |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | CRBN 82/4885LMNA 647/4885PKM 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.